Please wait a minute...
Journal of Neurorestoratology  2019, Vol. 7 Issue (2): 101-108    doi: 10.26599/JNR.2019.9040012
Research Article     
Decreased Npas4 expression in patients with post-stroke depression
Shina Gu1, Xiaodan Li2,3, Lin Zhao2,3, Huicong Ren2,3, Chendi Pei3,4, Wenqiang Li2,3, Junlin Mu2,3, Jinggui Song3,5,(✉), Zhaohui Zhang2,3,(✉)
1 Department of General Medicine, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453002, Henan, China
2 Department of Psychosomatic Medicine, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang 453002, Henan, China
3 Henan Key Lab of Biological Psychiatry, Xinxiang Medical University, Xinxiang 453002, Henan, China
4 Department of Neurology, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang 453002, Henan, China
5 Department of Neurology, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang 453002, Henan, China
Download: PDF (1163 KB)      HTML
Export: BibTeX | EndNote (RIS)      

Abstract  Purpose:

Post-stroke depression (PSD) is a frequent neuropsychiatric disorder following stroke which is associated with poor outcome. Neuronal Per-Arnt-Sim (PAS) domain protein 4 (Npas4) is associated with cognitive function. Npas4 expression in peripheral blood mononuclear cells (PBMCs) from patients with PSD was measured to find new therapeutic strategy.

Patients and methods:

Ischemic stroke patients (n = 152) within 1 week of stroke onset were recruited. At 3 months follow-up, the patients were divided into a PSD group (n = 77) and a stroke group (n = 75) using the Hamilton Rating Scale. Healthy subjects (n = 75) were also recruited in the study. The PSD group received 12 weeks of duloxetine treatment. Cognitive function was evaluated using the P300 test. Npas4 expression in PBMCs was measured by quantitative RT-PCR (qPCR).

Results:

Before treatment, P300 latencies in the PSD group were prolonged and the P300 amplitudes were lower than the control group (P < 0.01). Npas4 expression in the PSD group was also lower than the control group (P < 0.01). After treatment, the P300 latencies were reduced and the amplitudes were significantly elevated in the PSD group compared to that before treatment (P < 0.01). Meanwhile, Npas4 levels were significantly higher than that before treatment (P < 0.01). Npas4 expression was positively correlated to the P300 amplitudes (P < 0.05).

Conclusion:

Changes of Npas4 expression in PBMCs are associated with cognitive impairment in PSD patients and new therapeutic options applying Npas4-related transcript mechanism could be considered in the future.



Key wordsstroke      depression      Npas4     
Received: 29 April 2019      Published: 28 June 2019
Corresponding Authors: Jinggui Song,Zhaohui Zhang   
Cite this article:

Shina Gu, Xiaodan Li, Lin Zhao, Huicong Ren, Chendi Pei, Wenqiang Li, Junlin Mu, Jinggui Song, Zhaohui Zhang. Decreased Npas4 expression in patients with post-stroke depression. Journal of Neurorestoratology, 2019, 7: 101-108.

URL:

http://jnr.tsinghuajournals.com/10.26599/JNR.2019.9040012     OR     http://jnr.tsinghuajournals.com/Y2019/V7/I2/101

PSD (n = 77)Stroke (n = 75)Control (n = 75)pa
Baseline characteristics
Age (years)63.00 ± 8.3964.41 ± 8.1365.64 ± 7.750.135
Female population68.8%50.6%46.7%0.013
Education (years)6.29 ± 3.416.09 ± 3.786.71 ± 2.800.520
Widowhood27.3%11.5%13.1%0.009
Admission median NIHSS score6.36 ± 1.914.64 ± 2.5500
Living with offspring50.6%72.1%67.2%0.018
Laboratory findings
White cell count (109/L)7.15 ± 0.745.1 ± 0.865.43 ± 1.170.001
Glucose level (mmol/L)4.94 ± 0.514.87 ± 0.374.86 ± 0.450.927
TG level (mmol/L)2.53 ± 0.843.12 ± 1.142.70 ± 0.190.336
Hs-CRP level (mg/L)1.41 ± 0.161.37 ± 0.621.19 ± 0.190.139
Table 1Baseline characteristics of patient groups.
GroupnP300 Latencies (ms)P300 Amplitude (μV)Relative Npas4 expression
PSD77368.42 ± 15.17*3.39 ± 2.30*0.81 ± 0.15*
Stroke75346.39 ± 24.02*5.53 ± 3.33*1.72 ± 0.50*
Control75323.60 ± 18.558.76 ± 2.461.09 ± 0.43
F 99.7574.31105.721
P 0.0000.0000.000
Table 2Comparisons of P300 and Npas4 expression before treatment.
Fig. 1P300 latencies before and after treatment in patients with PSD. #, P < 0.01, compared with before treatment.
Fig. 2P300 amplitude before and after treatment in patients with PSD. #, P < 0.01, compared with before treatment.
Fig. 3Relative Npase4 expression before and after treatment in patients with PSD. #, P < 0.01, compared with before treatment.
Fig. 4Correlation between relative Npase4 expression and P300 Latencies in patients with PSD.
Fig. 5Correlation between relative Npase4 expression and P300 amlitudes in patients with PSD.
[1]   Hackett ML, Pickles K. Part I: frequency of depression after stroke: an updated systematic review and meta-analysis of observational studies. Int J Stroke. 2014, 9(8): 1017-1025.
[2]   Loubinoux I, Kronenberg G, Endres M, et al. Post-stroke depression: mechanisms, translation and therapy. J Cell Mol Med. 2012, 16(9): 1961-1969.
[3]   Hochstenbach JB, Anderson PG, van Limbeek J, et al. Is there a relation between neuropsychologic variables and quality of life after stroke? Arch Phys Med Rehabil. 2001, 82(10): 1360-1366.
[4]   Wu DL, Rastinejad F. Structural characterization of mammalian bHLH-PAS transcription factors. Curr Opin Struct Biol. 2017, 43: 1-9.
[5]   Bloodgood BL, Sharma N, Browne HA, et al. The activity- dependent transcription factor NPAS4 regulates domain- specific inhibition. Nature. 2013, 503(7474): 121-125.
[6]   Coutellier L, Gilbert V, Shepard R. Npas4 deficiency increases vulnerability to juvenile stress in mice. Behav Brain Res. 2015, 295: 17-25.
[7]   Choy F, Klari? T, Koblar S, et al. The role of the neuroprotective factor npas4 in cerebral ischemia. IJMS. 2015, 16(12): 29011-29028.
[8]   Jaehne EJ, Klari? TS, Koblar SA, et al. Effects of Npas4 deficiency on anxiety, depression-like, cognition and sociability behaviour. Behav Brain Res. 2015, 281: 276-282.
[9]   Mao GS, Wang YL, Guo XL, et al. Neurorestorative effect of olfactory ensheathing cells and Schwann cells by intranasal delivery for patients with ischemic stroke: design of a multicenter randomized double-blinded placebo-controlled clinical study. J Neurorestoratology. 2018, 6(1): 74-80.
[10]   First MB, Donovan S, Frances A. Nosology of chronic mood disorders. Psychiatr Clin North Am. 1996, 19(1): 29-39.
[11]   Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960, 23(1): 56-62.
[12]   Zhang LS, Hu XY, Yao LY, et al. Prophylactic effects of duloxetine on post-stroke depression symptoms: an open single-blind trial. Eur Neurol. 2013, 69(6): 336-343.
[13]   Kotsopoulos J, Zhang S, Akbari M, et al. BRCA1 mRNA levels following a 4~6-week intervention with oral 3,3'- diindolylmethane. Br J Cancer. 2014, 111(7): 1269-1274.
[14]   Coutellier L, Beraki S, Ardestani PM, et al. Npas4: a neuronal transcription factor with a key role in social and cognitive functions relevant to developmental disorders. PLoS One. 2012, 7(9): e46604. DOI:10.1371/journal.pone.0046604.
[15]   Shimizu E, Hashimoto K, Okamura N, et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry. 2003, 54(1): 70-75.
[16]   Risetti M, Formisano R, Toppi J, et al. On ERPs detection in disorders of consciousness rehabilitation. Front Hum Neurosci. 2013, 7: 775.
[17]   Yang T, Zhang L, Xiang MQ, et al. Cognitive impairment and gray matter volume abnormalities in silent cerebral infarction. Neuroreport. 2015, 26(15): 890-895.
[18]   Li XO, Yan YN, Wei WS. Identifying patients with poststroke mild cognitive impairment by pattern recognition of working memory load-related ERP. Comput Math Methods Med. 2013, 2013: 658501.
[19]   Lin YX, Bloodgood BL, Hauser JL, et al. Activity-dependent regulation of inhibitory synapse development by Npas4. Nature. 2008, 455(7217): 1198-1204.
[20]   Luscher B, Shen Q, Sahir N. The GABAergic deficit hypothesis of major depressive disorder. Mol Psychiatry. 2011, 16(4): 383-406.
[21]   Sanacora G, Mason GF, Rothman DL, et al. Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 1999, 56(11): 1043-1047.
[22]   Guidotti G, Calabrese F, Auletta F, et al. Developmental influence of the serotonin transporter on the expression of npas4 and GABAergic markers: modulation by antidepressant treatment. Neuropsychopharmacology. 2012, 37(3): 746-758.
[23]   Zhang ZH, Fei PG, Mu JL, et al. Decreased expression of neuronal Per-Arnt-Sim domain protein 4 gene in the hippocampus of a post-stroke depression rat model. Exp Ther Med. 2014, 7(4): 1045-1049.
[1] Xiaoling Guo, Qun Xue, Jianhua Zhao, Yi Yang, Yang Yu, Dezhong Liu, Jing Liu, Wenwu Yang, Linsen Mu, Ping Zhang, Tianyi Wang, Hongyan Han, Shoufeng Liu, Yuhua Zhu, Tao Wang, Chuanqiang Qu, Chuanqiang Qu. Clinical diagnostic and therapeutic guidelines of stroke neurorestoration (2020 China version)[J]. Journal of Neurorestoratology, 2020, 8(4): 241-251.
[2] Yunliang Wang, Xiaoling Guo, Jun Liu, Zuncheng Zheng, Ying Liu, Wenyong Gao, Juan Xiao, Yanqiu Liu, Yan Li, Manli Tang, Linlin Wang, Lin Chen, Di Chen, Deqiang Guo, Fei Liu, Weidong Chen, Baomin Chan, Bo Zhou, Aibing Liu, Gengsheng Mao, Hongyun Huang. Olfactory ensheathing cells in chronic ischemic stroke: A phase 2, double-blind, randomized, controlled trial[J]. Journal of Neurorestoratology, 2020, 8(3): 182-193.
[3] Miaomiao Zhuang, Qingheng Wu, Feng Wan, Yong Hu. State-of-the-art non-invasive brain–computer interface for neural rehabilitation: A review[J]. Journal of Neurorestoratology, 2020, 8(1): 12-25.
[4] Weiwei Zhao,Chuanguang Ju,Daozhen Wang,Huifen Shen. Clinical observation of effects of ultrashort wave therapy combined with acupuncture and rehabilitation training in the treatment of patients with dysphagia after stroke[J]. Journal of Neurorestoratology, 2019, 7(3): 136-142.
[5] Xiaoling Guo, Xin Wang, Yan Li, Bo Zhou, Weidong Chen, Lihua Ren. Olfactory ensheathing cell transplantation improving cerebral infarction sequela: a case report and literature review[J]. Journal of Neurorestoratology, 2019, 7(2): 82-88.
[6] Gengsheng Mao, Yunliang Wang, Xiaoling Guo, Jun Liu, Zuncheng Zheng, Lin Chen. Neurorestorative effect of olfactory ensheathing cells and Schwann cells by intranasal delivery for patients with ischemic stroke: design of a multicenter randomized double-blinded placebo-controlled clinical study[J]. Journal of Neurorestoratology, 2018, 6(1): 74-80.
[7] Ye Zhang, Hong Deng, Chao Pan, Yang Hu, Qian Wu, Na Liu, Zhouping Tang. Mesenchymal stromal cell therapy in ischemic stroke[J]. Journal of Neurorestoratology, 2016, 4(1): 79-84.
[8] Liyan Qiao, Jun Lu, Hongyun Huang. Clinical neurorestorative progress in stroke[J]. Journal of Neurorestoratology, 2015, 3(1): 63-72.